<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226574</url>
  </required_header>
  <id_info>
    <org_study_id>RTX-001</org_study_id>
    <nct_id>NCT03226574</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain</brief_title>
  <official_title>A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult
      subjects with intractable pain associated with cancer in any area below the mid-thoracic
      level who meet all other eligibility criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects who received RTX will be included in the analyses and summaries of safety,
      efficacy, PD, and PK assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The design uses a traditional &quot;3+3&quot; rule-based design that does not stipulate any prior assumption of the dose-toxicity curve. Dose escalation is permitted between successive cohorts based upon a specified algorithm, using discrete dosage steps.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>3-month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>3-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative Sensory Testing (QST)</measure>
    <time_frame>Screening, Day1, Day2, Day3, Day4, Day8 and Day90</time_frame>
    <description>Anatomical extent of RTX by diode laser or thermal probe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Pain Rating Scale (NPRS)</measure>
    <time_frame>Day-14 and Day1 to Day90 twice daily</time_frame>
    <description>Average daily pain and average worst daily pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily analgesic consumption (DAC) log</measure>
    <time_frame>Day-14 and Day1 to Day90 daily</time_frame>
    <description>consumption of analgesic compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory-Short Form (BPI-SF)</measure>
    <time_frame>Day-14, Day1, Day8, Day15, Day30, Day60 and Day90</time_frame>
    <description>Quality of life compared to baseline by the total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Questionnaire (NPQ)</measure>
    <time_frame>Day-14, Day1, Day2, Day3, Day4, Day8 and Day90</time_frame>
    <description>Neuropathic pain</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Intractable Cancer-related Pain</condition>
  <arm_group>
    <arm_group_label>RTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiniferatoxin</intervention_name>
    <description>single dose (0.4, 1, 2, 4, 8, or 15 mcg), epidural injection</description>
    <arm_group_label>RTX</arm_group_label>
    <other_name>RTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced cancer or metastasis, which has not responded to
             standard therapy, producing intractable chronic pain in the target area.

          -  Male or female subjects must be at least 18 years of age.

          -  Must have average worst pain score within specific range on the NPRS from assessment.

          -  Subjects not seeking or receiving potentially curative therapies for cancer.

          -  Sexually active female and male subjects must be willing to use an effective method to
             avoid pregnancies.

          -  Must be willing and capable of understanding and cooperating with the requirements of
             the study.

          -  Must be able to understand and complete study-related forms and adequately communicate
             in English.

          -  Must have provided written informed consent prior to participating in any
             study-related activity.

          -  Ability to discriminate intensity of thermal stimuli using QST.

          -  Subjects able to complete the study duration.

        Exclusion Criteria:

          -  Subjects with leptomeningeal metastases in lumbar area.

          -  Undergoing or have plans to undergo changes to current cancer treatment.

          -  Had prior lumbar spine surgical procedures that could impair the ability to perform
             the injection.

          -  Evidence of brain pathology or increase intracranial pressure.

          -  Presence of an IT shunt.

          -  Has evidence or a coagulopathy or hemostasis problem.

          -  Subjects not below specific total neutrophil count.

          -  Subjects above specific amount of serum creatinine.

          -  Evidence of an infection within 7 days of planned injection.

          -  Has an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic
             contrast agents.

          -  Female subjects who are pregnant, are planning on becoming pregnant, or are currently
             breastfeeding.

          -  Subjects with medical condition that could adversely impact the study participation or
             assessments.

          -  Subjects who have participated in a clinical trial within 30 days of Screening or are
             scheduled to receive an investigational product.

          -  Subjects with additional loci of pain above the mid-thoracic level or other pain
             disorder due to non-cancer etiology.

          -  Liver cirrhosis or severe hepatic impairment with function test 3 times above ULN.

          -  Sensory/peripheral neuropathy.

          -  Nonstudy related surgical procedures prior to IP administration.

          -  Subjects who have not completely recovered from any toxicities from previous
             treatments.

          -  Arterial or venous thrombi (including stroke), myocardial infarction, admission for
             unstable angina, cardiac angioplasty, or stenting.

          -  Corrected QT using Fridericia's formula (QTcF) prolongation.

          -  Evidence or history of bleeding disorder.

          -  Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of
             chronic hepatitis B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Takeshita, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Stannard, BS, CCRP, CCRC</last_name>
    <phone>8582034100</phone>
    <email>bstannard@semnurpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sorrento investigational site</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sorrento investigational site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resiniferatoxin</keyword>
  <keyword>RTX</keyword>
  <keyword>Cancer pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

